It is my experience that the owner of the clinic that purchases the biologic or chemo drug decides which to use - not the doc. It is almost always a large organization and the bottom line is 99% of the decision. A branded drug will hold little advantage over a cheaper generic to the PharmD in charge of the formulary. The patient won't know, nor care.
Roche will have two choices. Either cut the rate for the IV or try to sell the clinic on the cost advantages of the SC product. I think time is on Halo's side.
News 
Market Data 
Discover 
